Ascendis Pharma A/S (ASND) NASDAQ

213.23

+7.42(+3.61%)

Updated at June 09 04:00PM

Currency In USD

Key Executives

Name	Title	Year Born
Jan Moller Mikkelsen	President, Chief Executive Officer, Member of Executive Board & Executive Director	1960
Joseph Kelly	Head of U.S. Commercial of Endocrinology	1969
Mads Bodenhoff	Senior Vice President, Head of Finance & Principal Accounting Officer	1970
Kennett Sprogoe	Executive Vice President and Head of Research & Product Development	1979
Chad Fugure	Vice President of Investor Relations	N/A
Flemming Steen Jensen	Executive Vice President of Product Supply & Quality	1961
Scott T. Smith	Chief Financial Officer, Executive Vice President & Member of Executive Board	1974
Stina Singel	Executive Vice President & Head of Clinical Development for Oncology	1974
Michael Wolff Jensen	Executive Vice President, Chief Legal Officer & Member of the Executive Board	1971
Pedersen Anni Lotte Kirstine Sonderbjerg	Executive Vice President, Chief Administrative Officer & Member of the Executive Board	1961

Name

Title

Pay

Year Born

Jan Moller Mikkelsen

President, Chief Executive Officer, Member of Executive Board & Executive Director

1960

Joseph Kelly

Head of U.S. Commercial of Endocrinology

1969

Mads Bodenhoff

Senior Vice President, Head of Finance & Principal Accounting Officer

1970

Kennett Sprogoe

Executive Vice President and Head of Research & Product Development

1979

Chad Fugure

Vice President of Investor Relations

N/A

Flemming Steen Jensen

Executive Vice President of Product Supply & Quality

1961

Scott T. Smith

Chief Financial Officer, Executive Vice President & Member of Executive Board

1974

Stina Singel

Executive Vice President & Head of Clinical Development for Oncology

1974

Michael Wolff Jensen

Executive Vice President, Chief Legal Officer & Member of the Executive Board

1971

Pedersen Anni Lotte Kirstine Sonderbjerg

Executive Vice President, Chief Administrative Officer & Member of the Executive Board

1961

Description

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.